Blandt vaccinerede patienter, som udviklede zoster, reducerede ZOSTAVAX signifikant de generelle akutte og kroniske zosterassocierede smerter i forhold til placebo.
Among vaccinated individuals who developed zoster, ZOSTAVAX significantly reduced overall acute and chronic zoster-associated pain compared with placebo.